| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2878150 | The Annals of Thoracic Surgery | 2010 | 8 Pages |
Abstract
Stage I adenocarcinoma of the lung recurs. Identifying high-risk patients will simplify decision making for adjuvant therapy and surveillance. Thorough mediastinal lymphadenectomy dissociates tumor size as a predictor of survival and may itself provide an important survival benefit.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sudish C. MD, PhD, Scott I. MD, Ugochukwu C. MD, Carol F. MD, Andrea MD, Lillian H. MS, Edward R. MD, MS, Tarek M. MD, David P. MD, Thomas W. MD, Eugene H. MD,